Is Hepatitis B Curable, and Does It Go Away?

The result arrives in the least dramatic way possible: a line in a patient portal, sandwiched between a normal cholesterol reading and a vitamin D level. “Hepatitis B surface antigen: positive.” No symptoms. No memory of feeling ill. Just a routine blood test before a new job, a pregnancy, or a blood donation, and now a phone screen at eleven at night asking a search engine whether this thing can be cured.

The answer people find is confusing because it is actually two answers. Some websites say hepatitis B clears up on its own. Others describe lifelong medication and liver scans. Both are correct, depending on which version of the infection is being discussed and how old the person was when the virus arrived.

What follows is the fuller picture: why the body usually wins, why it sometimes does not, what “cure” means to a liver specialist versus a headline writer, and what a positive result realistically changes about the years ahead.

Is hepatitis B curable? The honest answer depends on which hepatitis B you mean

Two quite different situations share one name. Acute hepatitis B is the first six months after the virus enters the body. Chronic hepatitis B is what doctors call it when the virus is still detectable after those six months have passed. The word “curable” behaves differently in each.

For acute infection, the body itself is usually the cure. The immune system recognizes infected liver cells, clears them, and leaves behind antibodies that protect for life. Nobody prescribes that outcome; it simply happens in most adults.

For chronic infection, medicine cannot yet reliably remove the virus. What it can do is hold the virus down, often to the point where it is undetectable in blood, and in doing so lower the risk of scarring and liver cancer. The World Health Organization estimated that 254 million people were living with chronic hepatitis B in 2022, and that the infection caused about 1.1 million deaths that year, mostly from cirrhosis and liver cancer. Those numbers explain why the search for a cure is so active, and also why suppression, the tool available now, matters so much.

There is a third scenario worth knowing about: a minority of people with chronic infection eventually lose the surface antigen from their blood, a state researchers call a functional cure. It is uncommon, but it is real, and it is the target that most experimental therapies are chasing.

So the most useful question is rarely “is it curable?” It is “which stage am I in, and is my liver being watched?”

Why does acute hepatitis B usually go away on its own?

Picture the liver as an apartment building with several hundred billion residents. When hepatitis B moves in, it does not smash windows; it quietly sets up in individual cells and uses them to make copies of itself. For weeks the building looks normal. The incubation period, according to the CDC, ranges from 60 to 150 days, with an average of about 90.

Then the immune system notices. Specialized T cells identify infected liver cells and remove them, which is what causes the inflammation, fatigue, and sometimes jaundice of an acute episode. The illness people feel is, paradoxically, the sound of the body winning. As infected cells are cleared, antibodies against the virus’s surface protein appear and stay for life, which is why a person who has recovered cannot catch hepatitis B again.

The NHS puts it plainly: most adults infected with hepatitis B are able to fight off the virus and fully recover within a couple of months. The WHO adds that fewer than 5 percent of adults who are infected go on to develop chronic infection.

Recovery does not mean the encounter is erased. A specific antibody to the virus’s core protein remains detectable indefinitely, and tiny amounts of viral genetic material can persist in liver cells even after clearance. Under ordinary circumstances that leftover template is inert. Under heavy immune suppression, such as some cancer treatments, it can occasionally wake up, which is why clinicians ask about past hepatitis B before starting such therapies.

What decides whether hepatitis B becomes chronic?

Age at infection is the single biggest factor, and the difference is dramatic. An adult’s mature immune system usually clears the virus. A newborn’s immune system, still learning what belongs and what does not, tends to tolerate it, and the virus settles in for decades.

Age when infected	Share who develop chronic infection
During the first year of life	80 to 90 percent
Before age 6	30 to 50 percent
Adulthood, otherwise healthy	Less than 5 percent

Those figures come from the WHO fact sheet on hepatitis B, and they reshape how the disease should be understood. Most chronic hepatitis B in the world was not acquired through adult behavior. It was acquired at birth or in early childhood, often from a mother who did not know she carried the virus, or from household contact in regions where the infection is common.

A second factor is immune health. People whose immune systems are weakened, for example by advanced kidney disease or immune-suppressing treatment, are more likely to remain infected after an adult exposure.

This is why a positive test in an adult who feels well often points backwards in time. The virus may have been present since infancy, quietly, and only now has a routine blood draw brought it into view. That reframing matters for the person holding the result: it is not evidence of anything they did recently, and it is not a reason for shame.

Why is chronic hepatitis B so hard to cure?

Hepatitis C, another liver virus, can now be cured with a short course of tablets in most people. Hepatitis B stubbornly cannot, and the reason sits inside the nucleus of the liver cell.

When hepatitis B infects a cell, it converts its genetic material into a stable, ring-shaped form that parks itself in the nucleus alongside the cell’s own chromosomes. Scientists call this covalently closed circular DNA, or cccDNA. Think of it as a master template locked in a filing cabinet. The virus uses that template to print new copies of itself for as long as the cell lives, and liver cells live a long time.

Current antiviral medicines work like a jammed photocopier. They block the enzyme the virus needs to copy its genetic material, so new virus particles stop flowing out into the blood. The master template in the filing cabinet, though, is untouched. Stop the medicine and the copier restarts.

Fragments of the viral genome can also integrate directly into the human DNA of liver cells. Those fragments cannot produce complete virus, but they can keep producing the surface protein that shows up on blood tests, and they are thought to contribute to the long-term cancer risk.

Layer on top of this a tired immune system. After years of exposure, the T cells that should attack infected cells become exhausted and unresponsive. A cure would need to do three things at once: silence the template, remove or neutralize integrated fragments, and re-energize the immune response. No single approach has managed all three, which is why the honest word from researchers is still “toward,” not “achieved.”

What does a functional cure for hepatitis B actually mean?

Read any research headline about a hepatitis B cure and the word “functional” is usually hiding in the fine print. It has a specific meaning, and understanding it protects against both false hope and unnecessary despair.

A functional cure means the surface antigen has disappeared from the blood, viral DNA is undetectable, and both remain that way after treatment has stopped. Sometimes the person develops antibodies against the surface protein as well, which looks very similar to the blood picture of someone who recovered from an acute infection years earlier. The liver, freed from constant viral activity, stops accumulating damage, and long-term risks fall substantially.

What a functional cure does not mean is that the virus is gone. The master template described earlier, the cccDNA, can still be present in a small number of liver cells. It is dormant rather than deleted. For this reason, clinicians continue to monitor people after a functional cure and remain alert to reactivation if the immune system is later suppressed.

Researchers distinguish two further categories. A partial cure is sustained undetectable viral DNA off treatment while the surface antigen persists. A complete or sterilizing cure would eliminate every trace of viral template from every liver cell. The second is, at present, a theoretical goal rather than a clinical one.

Functional cure does occur spontaneously in a small proportion of people with chronic infection each year, and it is the endpoint most clinical trials now aim for. When a headline promises a cure, it is almost always this definition being used. That is a meaningful achievement, and it is still not the same as never having had the virus.

How is chronic hepatitis B treated today?

Two broad approaches exist, and they work in opposite directions: one restrains the virus, the other tries to rouse the immune system.

The first and most widely used approach is a daily oral antiviral. These medicines block the viral enzyme that copies genetic material, so the amount of virus in the blood falls, often to undetectable levels within months. Liver inflammation quiets, scarring can slow or partially reverse, and the long-term risk of cirrhosis and liver cancer decreases. The trade-off is duration: because the master template survives, treatment is usually long-term and for many people indefinite. Stopping is a specialist decision, since the virus can rebound.

The second approach is an injectable immune-modulating treatment given for a fixed period rather than indefinitely. It aims to help the body’s own defenses recognize and control infected cells. It is used less often because it has more side effects and suits a narrower group of people, but for some it offers the possibility of a defined finish line.

Neither approach eliminates the virus outright. Both are chosen, adjusted, and, where appropriate, stopped by the treating clinician based on viral load, liver enzyme levels, the degree of scarring, age, other health conditions, and personal circumstances. Any figures a patient sees online about how well treatment works should be read against that reality: outcomes are measured in years of protection, not in a single cure event.

People on long-term antivirals still need regular monitoring. Treatment lowers risk; it does not remove the need for surveillance.

Does everyone with chronic hepatitis B need treatment?

Not immediately, and not always. Chronic hepatitis B moves through phases over a lifetime, and the phase determines whether medicine is likely to help.

In some phases the virus replicates heavily but the immune system leaves it alone, so liver enzymes stay normal and damage is minimal. In others the immune system attacks, enzymes rise, and inflammation accumulates. Later, many people enter a quieter state sometimes called an inactive carrier phase, with low viral levels and little inflammation. The phases can shift, occasionally back toward activity, which is why observation never truly ends.

For decades, guidelines recommended treatment mainly for people with active inflammation or significant scarring, and watchful monitoring for everyone else. That thinking has been evolving. The WHO’s 2024 guidance broadened the criteria so that more people qualify for treatment earlier, reflecting evidence that long-term suppression protects the liver and lowers transmission.

Whatever the criteria, the gap between need and reality is stark. The WHO reported that in 2022 only 13 percent of people living with hepatitis B had been diagnosed, and only about 3 percent were receiving antiviral treatment. Most people with the virus do not know they have it.

Monitoring, for those not on treatment, typically involves blood tests every six to twelve months for liver enzymes and viral DNA, and periodic ultrasound of the liver for those at higher cancer risk. The decision to start, continue, or stop medicine always rests with the specialist who has the full picture, and it can change as the phase changes.

What are the symptoms of hepatitis B, and why do most people have none?

Ask for five symptoms of hepatitis B and a textbook will oblige. Mayo Clinic lists these among the classic signs of an acute episode:

• Yellowing of the skin and the whites of the eyes (jaundice)
• Dark urine, often described as tea- or cola-colored
• Profound fatigue and weakness
• Nausea, vomiting, and loss of appetite
• Pain in the abdomen, typically under the right ribs where the liver sits

Fever and joint pain round out the picture. These usually appear one to four months after exposure, last a few weeks, and fade as the immune system clears the virus.

The more important truth is the one the list hides. Many people with acute infection have symptoms so mild they mistake them for a passing bug, and young children almost never show symptoms at all. Chronic hepatitis B is quieter still. A person can carry the virus for thirty or forty years without a single day of illness while inflammation slowly scars the liver. When symptoms finally appear in chronic disease, they often signal advanced damage: swelling of the abdomen or legs, easy bruising, confusion, or vomiting blood.

This silence is why hepatitis B is found by screening far more often than by symptoms. It also means feeling well is not evidence that the liver is well. Someone told their infection is “inactive” still needs the scheduled blood tests, because the virus does not send a warning before it shifts phase.

How do you catch hepatitis B? Is it only a sexually transmitted infection?

Hepatitis B is sexually transmissible, but calling it an STD and stopping there misses most of how it spreads worldwide.

The virus travels in blood, semen, and vaginal fluids. According to the CDC, transmission happens through sex with an infected partner, sharing needles or injection equipment, direct contact with infected blood or open sores, needlestick injuries, and from mother to baby during birth. Sharing personal items that can carry traces of blood, such as razors, toothbrushes, or nail clippers, is another route. The virus is hardy: the CDC notes it can survive on surfaces for at least seven days and still cause infection.

Globally, mother-to-child transmission and early childhood exposure account for the majority of chronic infection, which is why so many people diagnosed as adults have carried the virus since birth and have never engaged in any behavior they would consider risky.

Equally important is what does not spread hepatitis B. The CDC is explicit that it is not transmitted through food or water, sharing eating utensils, breastfeeding, hugging, kissing, holding hands, coughing, or sneezing. A parent with hepatitis B can cook for their family and cuddle their children. A colleague with hepatitis B poses no risk across a shared desk.

Getting the routes right matters for two reasons. It removes unwarranted stigma from a diagnosis that is, in most cases, an accident of birth. And it focuses prevention where it works: protecting newborns, screening in pregnancy, safe injection practices, and not sharing items that may carry blood.

Can you still get hepatitis B if you were vaccinated?

It is possible, though uncommon, and the reasons are worth separating because each has a different practical implication.

The vaccine works by teaching the immune system to make antibodies against the virus’s surface protein. The CDC describes the resulting protection as long-lasting in people who respond. Most people do respond, but a minority do not produce a measurable antibody level after the full series. Non-response is more likely in older adults, people with obesity, those with advanced kidney disease, and people whose immune systems are suppressed. For those in higher-risk roles, such as healthcare workers, a blood test after vaccination confirms whether protection was achieved, and a clinician can advise on next steps if it was not.

A second scenario is infection that predates vaccination. Someone infected at birth or in early childhood who was vaccinated later in life would have received the vaccine after the virus was already established. Vaccination does not treat an existing infection and cannot clear it; it can only prevent a new one. Screening before vaccination, particularly for adults from regions where hepatitis B is common, identifies this situation.

A third, rarer possibility involves incomplete series or exposure before the series had time to take effect.

For anyone who was vaccinated and later tests positive for the surface antigen, the sensible response is not to question the entire history but to ask two questions of the clinician: was I likely infected before I was vaccinated, and did I ever have my antibody level checked? The answers usually explain the result.

Can a person with hepatitis B live a normal life?

Yes, and the evidence supports saying so without hedging. Most people with chronic hepatitis B work, study, exercise, travel, marry, and raise children, and the infection stays in the background of their lives, checked by a blood test or two each year.

The adjustments that genuinely matter are few and specific. Alcohol is the largest. A liver already coping with a virus handles alcohol poorly, and the NHS advises people with hepatitis B to avoid it or keep intake very low. Other medicines and supplements deserve a mention to the clinician, since some are processed by the liver. Cleveland Clinic and the NHS both suggest routine steps to protect others: covering cuts, not sharing razors or toothbrushes, and informing sexual partners and household members so they can be tested and, if needed, protected.

Pregnancy is possible and common. Screening during pregnancy allows steps to be taken around birth that dramatically reduce the chance of passing the virus to the baby, which is the single most effective intervention against chronic hepatitis B worldwide. Breastfeeding is safe.

Fatigue is the symptom people most often ask about. In chronic infection without active inflammation it is usually no more common than in the general population, and a clinician can help sort out other causes.

What a normal life with hepatitis B does require is a relationship with a clinic and a calendar. The visits are brief, the tests are routine, and their purpose is to catch any change while it is still small. That commitment, more than any restriction, is what keeps the infection from shaping the years ahead.

What blood tests show whether hepatitis B has gone away?

Hepatitis B leaves a signature in the blood that reads like a timeline, and learning a few of its markers turns a bewildering lab report into something that can be followed.

The surface antigen, often written HBsAg, is a protein from the virus’s outer coat. Its presence means the virus is in the body. If it is still present six months after infection, the infection is defined as chronic. Its disappearance is the key marker of clearance, whether that clearance happens naturally in an acute episode or as a functional cure years later.

The surface antibody, anti-HBs, appears when the immune system has learned to neutralize the virus. It signals immunity, either from recovery or from vaccination.

The core antibody, anti-HBc, shows that the body has encountered the actual virus at some point. It persists for life and is absent in people whose immunity comes only from vaccination, which is how a clinician tells the two apart.

Viral DNA, measured as HBV DNA, quantifies how actively the virus is replicating. It guides treatment decisions and tracks response. A related marker, the e antigen, indicates high replication when present.

Liver enzymes, especially ALT, are not tests for the virus itself but for the inflammation it may be causing.

Someone who recovered from an acute infection typically shows surface antigen negative, surface antibody positive, and core antibody positive. Someone with chronic infection shows surface antigen positive, surface antibody negative, core antibody positive. MedlinePlus offers a plain-language guide to these patterns, and it is worth a read before an appointment so the conversation starts from understanding rather than alarm.

When should you see a doctor about hepatitis B?

Some situations call for a scheduled appointment; a few call for the same day.

Seek urgent medical care if any of the following appear, whether or not hepatitis B has already been diagnosed: yellowing of the skin or eyes that develops quickly, confusion, unusual drowsiness or difficulty staying awake, vomiting blood or passing black, tarry stools, severe pain in the upper abdomen, rapid swelling of the belly or legs, or bleeding and bruising that seems out of proportion. Mayo Clinic and the NHS flag these as possible signs of acute liver failure or of decompensation in a scarred liver, both of which need hospital assessment without delay.

Time also matters after a possible exposure. Anyone who has had a needlestick injury, unprotected sex with a partner known to have hepatitis B, or contact with someone’s blood through a cut or bite should contact a clinician or emergency service promptly. Protective measures exist that work best when started within hours, and the window closes within days.

Beyond emergencies, a routine appointment is the right step for anyone who has never been tested and was born in a region where hepatitis B is common, whose parent or household member has the infection, who is pregnant, or who is about to start treatment that suppresses the immune system, including chemotherapy or certain arthritis and bowel disease medicines. A positive result on any hepatitis B test, however incidental, warrants a follow-up visit rather than a wait-and-see approach.

Finally, anyone already diagnosed who has drifted away from monitoring should simply return. The tests have not changed, and no one at the clinic will be surprised.

Where is hepatitis B cure research heading, and how should you read the headlines?

The phrase “cure for hepatitis B” appears in research news several times a year. Reading those stories well requires knowing what is being tested and what stage the testing has reached.

Most experimental strategies attack one of the three barriers described earlier. Some aim to silence the virus’s messenger molecules so infected cells stop producing the surface protein that floods the blood and dulls the immune response. Others block the virus from entering new liver cells or interfere with how it assembles its protective shell. A third group tries to reawaken exhausted T cells, using therapeutic vaccines or agents that release the brakes on the immune system. Increasingly, trials combine two or more of these with existing antivirals, on the theory that no single lever will be enough.

The endpoint in nearly all of these studies is functional cure: loss of the surface antigen that persists after treatment ends. Early trials report that outcome in some participants, and the proportions vary widely between approaches and between studies. None has yet reached the stage of routine clinical use, and a clinician cannot prescribe any of them outside a trial.

What this means for someone living with the virus today is not nothing. It means the standard of care they are receiving now is the foundation on which those future therapies are being built, and staying engaged in monitoring keeps them well placed to benefit if one arrives. It also means treating any announcement with a specific question: was the surface antigen still absent months after treatment stopped, and in how many people? The answers are usually in the paper, if not in the headline.

Frequently asked questions

Is hepatitis B curable?

Not yet in the way hepatitis C is, but it often resolves on its own. Most adults with a new infection clear the virus within a few months and become immune for life. Chronic infection, which persists beyond six months, cannot currently be eliminated by medicine, though daily antivirals can suppress the virus and protect the liver for years. A small minority of people with chronic infection eventually lose the surface antigen, an outcome researchers call a functional cure.

Does hepatitis B go away on its own?

In most adults, yes. The NHS notes that most adults fight off the virus and recover fully within a couple of months, and the WHO reports that fewer than 5 percent of infected adults develop chronic infection. The picture reverses in early life: most infants infected in their first year carry the virus long-term. Whether an infection has cleared is confirmed by blood tests, not by how a person feels.

Can a person with hepatitis B live a normal life?

Yes. Most people with chronic hepatitis B work, exercise, travel, have relationships, and raise families with the infection largely in the background. The main adjustments are avoiding or minimizing alcohol, telling clinicians about the diagnosis before starting new medicines, taking simple steps to protect household members and partners, and keeping regular monitoring appointments so any change in the liver is caught early. Pregnancy and breastfeeding are both possible with appropriate care.

Is hepatitis B only a sexually transmitted disease?

No. Hepatitis B can be passed through sex, but globally most chronic infections are acquired at birth from a mother carrying the virus or in early childhood through household contact. The virus also spreads through shared needles, needlestick injuries, and items that carry traces of blood such as razors and toothbrushes. It is not spread through food, water, casual contact, coughing, or breastfeeding, according to the CDC.

Can I still get hepatitis B even if I was vaccinated?

It is uncommon but possible. A minority of people do not produce protective antibodies after vaccination, particularly older adults and those with weakened immune systems or kidney disease. More often, a positive test in a vaccinated person reflects an infection acquired before vaccination, sometimes at birth, since the vaccine cannot clear an existing infection. A blood test can check antibody levels, and a clinician can interpret the result in context.

What are 5 symptoms of hepatitis B?

Mayo Clinic lists jaundice (yellow skin and eyes), dark urine, fatigue and weakness, nausea with loss of appetite, and pain in the upper right abdomen among the classic signs of acute infection, along with fever and joint pain. Many people, especially children, have no symptoms at all, and chronic infection can stay silent for decades. Feeling well is therefore not a reliable sign that the liver is unaffected.

How long does it take for hepatitis B to go away?

The CDC gives an incubation period of 60 to 150 days, averaging about 90, before symptoms appear. Once the immune response begins, acute illness typically lasts several weeks, and the NHS reports that most adults recover fully within a couple of months. If the surface antigen is still detectable in blood six months after infection, the infection is classified as chronic and is unlikely to clear without long-term monitoring or treatment.

What does a functional cure for hepatitis B mean?

A functional cure means the hepatitis B surface antigen has disappeared from the blood and viral DNA is undetectable, and both remain so after treatment has stopped. It is the main goal of current cure research. It differs from a complete cure because the virus’s dormant genetic template can persist in some liver cells, so people who achieve functional cure still need follow-up, particularly if their immune system is later suppressed.

Does everyone with chronic hepatitis B need medication?

Not necessarily. Chronic infection moves through phases, and treatment is most useful when the virus is actively damaging the liver or scarring has developed. People in quieter phases are usually monitored with blood tests every six to twelve months rather than treated immediately. Recent WHO guidance has widened who qualifies for treatment, but the decision always depends on viral levels, liver enzymes, scarring, age, and other conditions, assessed by the treating clinician.

When should I see a doctor about hepatitis B?

Seek urgent care for rapidly developing jaundice, confusion or extreme drowsiness, vomiting blood, black stools, severe abdominal pain, or sudden swelling of the abdomen or legs. Contact a clinician promptly after any possible exposure, such as a needlestick or unprotected sex with someone known to have the virus, because protective measures work best within hours. Anyone with a positive test, a family history, or plans to start immune-suppressing treatment should book a routine appointment.

References

• World Health Organization – Hepatitis B fact sheet
• CDC – About Hepatitis B
• NHS – Hepatitis B
• MedlinePlus – Hepatitis B

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.